Caspian Oliai is an Oncology physician affiliated with APLA Health. OpenAlex indexes 791 publications with 1,184 citations (h-index 18); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 Ucla Medical Plaza Suite 550
Los Angeles, CA 900958358
Telephone
310-794-4955Registry record last updated 15 Nov 2019.
Clinical trials
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Sponsor: Jonsson Comprehensive Cancer Center
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Sponsor: Jonsson Comprehensive Cancer Center
- CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Sponsor: Jonsson Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- National Marrow Donor ProgramProgram year20255 payments
- Novartis Pharmaceuticals CorporationProgram year20253 payments
- Autolus IncProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
59%Other antiemetics46%Fosaprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist12.8%Palonosetron hcl52%Ondansetron hydrochloride48%Part B, office-administered≥24 patients+ 1 more class in this area
Anti-infectives
28.2%Human Immunoglobulin G27.8%Immune globulin100%Part B, office-administered≥13 patientsTriazole and tetrazole derivatives0.2%Cresemba100%Part D<11 patients+ 1 more class in this area
Sensory organs
6.4%Corticosteroid6.4%Dexamethasone sodium phosphate100%Part B, office-administered≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ronald Mitsuyasu, MD
APLA Health
Aaron Lisberg, MD
APLA Health
Steven Mittelman, MD
APLA Health
Brigitte Gomperts, MD
APLA Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”